|
| Press Releases |
|
 |
|
| Tuesday, October 24, 2017 |
|
|
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar |
| SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market. more info >> |
|
| Tuesday, August 15, 2017 |
|
|
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances |
| Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications. more info >> |
|
| Thursday, June 15, 2017 |
|
|
First-Year Performance of Global Systematic Multi-Strategy Fund |
| The Board of Directors of Singapore eDevelopment Ltd ("SeD") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation. more info >> |
|
| Monday, May 22, 2017 |
|
|
Singapore eDevelopment's Global BioLife Initiates Research on New Universal Drug Platform |
| Singapore eDevelopment Ltd ("SeD"), through its subsidiary Global BioLife Inc. ("Global BioLife"), has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee, Mr Daryl Thompson. more info >> |
|
|
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform |
| Singapore eDevelopment Limited ("SeD") subsidiary Global BioLife Inc. has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 23:21 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 13, 2025 23:18 HKT/SGT
|
|
|
AI Inference vs. AI Training: What Are the Differences?
Aug 13, 2025 23:03 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 13, 2025 22:33 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 13, 2025 22:31 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 13, 2025 21:32 HKT/SGT
|
|
|
China Lilang Announces 2025 Interim Results
Aug 13, 2025 21:30 HKT/SGT
|
|
|
NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请
Aug 13, 2025 21:25 HKT/SGT
|
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 21:24: JST
|
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT/SGT
|
|
|
NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請
Aug 13, 2025 20:24 HKT/SGT
|
|
|
潼關黃金獲納入MSCI全球小型股指數 資本市場影響力進一步提升
Aug 13, 2025 19:19 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT/SGT
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 13:00: JST
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 12:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
